H.pylori infection
Conditions
Interventions
Minocycline Innovation Test Group:Selective treatment of amoxicillin or furazolidone combined with minocycline
Genetic optimization test group:After high-throughput second-generation sequencing of DNA, optimizing antibiotics based on drug resistance and sensitivity
Classic antibiotic control group:An empirical antibiotic medication that is not a previous option
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) Aged = 18 years old; (2) Clearly H.pylori infection (13C breath test positive or histopathological staining positive or rapid urease positive); (3) Had received at least 1 H.pylori eradication therapy, but determined that eradication failed; (4) The days of conforming eradication failure is more than 3 months.
Exclusion criteria
Exclusion criteria: (1) Digestive malignant tumors; (2) History of upper gastrointestinal surgery; (3) Antibiotics, proton pump inhibitors, H2 receptor antagonists, and expectorants have been used in the past 4 weeks; (4) There are symptoms that may related to malignant disease, such as gastrointestinal bleeding, persistent vomiting, weight loss, difficulty swallowing, abdominal mass, etc.; (5) Pregnant and lactating women; (6) Combine diseases such as severe heart, brain, lung, kidney and liver dysfunction; (7) Those who are allergic to the drugs used in this study protocol; (8) Those with poor compliance or non-cooperation such as mental symptoms and drug addiction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| C13 urea breath test;High-throughput sequencing; | — |
Countries
China
Contacts
Public ContactLuo Qingfeng
Beijing Hospital
Outcome results
None listed